10/8/2025 2:29:10 PM Kicking Off “Reel Talk:” Untangling the Web of IP in Entertainment with Bess Morgan By Anne Kennedy McGuire If you’re going to start a new series about the business of entertainment, it only makes sense to begin with someone who knows how to...
9/26/2025 5:49:44 PM Design Patents: An Underutilized Tool for Luxury Brand Protection By Jonathan B. Thielbar When people think of patents, things like technology, science and engineering often come to mind. But design patents are a different type...
8/29/2025 5:49:09 PM White House Executive Order Disbands Patent Examiners’ Union By Bill Kramer On Thursday, August 28, 2025, the President of the United States issued an Executive Order which effectively disbanded the union...
8/7/2025 8:38:24 PM AI and Patents: Practical Takeaways from Our Recent AI Roundtables By Jonathan B. Thielbar As artificial intelligence (AI) becomes increasingly embedded in product development and business operations, in-house legal teams are...
4/3/2025 9:34:23 PM The Landscape of Regeneron’s Eylea® Litigation—Update 1: the Federal Circuit Affirmed the District Court’s Decisions in Celltrion and Amgen By Loeb & Loeb After the Federal Circuit’s January decisions1 affirming the preliminary injunction orders that bar Samsung Bioepis (SB) and Formycon...
3/28/2025 7:15:47 PM USPTO Issues Significant Changes to Post-Grant Patent Review Procedures By Jonathan B. Thielbar This week, the U.S. Patent and Trademark Office (USPTO) issued a memorandum introducing new processes related to discretionary denials of...
3/27/2025 6:37:35 PM Introducing The Sports Law Playbook: Q1 2025 By Brian R. Socolow Alexander Loh Derek Crownover Scott Zolke +1 more... Show less Welcome to the inaugural issue of The Sports Law Playbook, Loeb & Loeb’s quarterly update bringing you the latest legal developments in...
3/3/2025 8:23:20 PM USPTO Rescinds PTAB Denial Guidelines By Bill Kramer This morning, in a likely pro-patent holder approach, the U.S. Patent and Trademark Office (USPTO) rescinded a guidance memorandum from...
2/19/2025 6:32:40 PM The Landscape of Regeneron’s Eylea® Litigation After the Federal Circuit Affirmed Two Preliminary Injunction Orders Blocking Biosimilar Market Entry By Loeb & Loeb A biosimilar is a biologic drug that is highly similar, but not identical, to an already approved biologic drug, i.e. the reference...
8/21/2024 7:43:24 PM Allergan Holding Protects "First-Filed" Parent Patents from Their Misbehaving Patent Offspring By Jonathan B. Thielbar This month, in Allergan USA, Inc. v. MSN Laboratories Private Ltd., the Federal Circuit added to the ongoing patent-family drama...
5/21/2024 5:19:50 PM USPTO's Proposed New Terminal Disclaimer Rule Would Change Applicant and Patent Challenger Strategy By Jonathan B. Thielbar The United States Patent and Trademark Office (USPTO) has proposed changes to terminal disclaimer rules that could significantly...
5/14/2024 10:10:17 PM GSK Joins COVID-19 mRNA Vaccine Patent War By Loeb & Loeb mRNA-Based Vaccine and Other Therapeutics mRNA-based vaccines have become one of the most discussed technologies both inside and outside...